Table 5 |
|
|
Adverse events reported in published studiesa during or after rituximab-induced B-cell depletion therapy |
|
|
Infections |
Pneumoniab |
|
Shinglesb |
|
|
Thigh abscess, subcutaneous abscess |
|
|
Urinary tract infection |
|
|
Septicaemia |
|
|
Psuedomonas infection |
|
|
Staphyloccal abscess |
|
|
Streptococcal viridans infection |
|
|
Necrotising fasciitis |
|
|
Fatal histoplasmosis |
|
|
Haematological |
Neutropeniab |
|
Pulmonary |
Pneumonia |
|
Pulmonary haemorrhage |
|
|
Pulmonary embolism |
|
|
Respiratory failurec |
|
|
Breathlessness |
|
|
Cardiac |
Cardiac failurec |
|
Fatal pancarditisc |
|
|
Pericarditis |
|
|
Tachycardia |
|
|
Neurological |
Insomnia |
|
Transient ischaemic attack |
|
|
Skin |
Localised or widespread rashb |
|
Pruritis |
|
|
Urticaria |
|
|
Miscellaneous |
Infusion reactionsb |
|
Serum sickness reaction |
|
|
Hypogammaglobulinaemia |
|
|
Anaphylaxis |
|
|
Deep vein thrombosis |
|
|
Dyspepsia |
|
|
Malaise |
|
|
Pyrexia |
|
|
Polyarthralgia |
|
|
|
|
|
aSee Table 1. bFrequently reported adverse event. cLife-threatening complications. |
|
|
Reddy et al. Arthritis Research & Therapy 2013 15(Suppl 1):S2 doi:10.1186/ar3910 |
|